- Home
- WINT vs PRTG Comparison
WINT vs PRTG Comparison
Compare WINT & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- PRTG
- Stock Information
- Founded
- WINT 1992
- PRTG 1973
- Country
- WINT United States
- PRTG British Virgin Islands
- Employees
- WINT N/A
- PRTG N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- PRTG Oil & Gas Production
- Sector
- WINT Health Care
- PRTG Energy
- Exchange
- WINT Nasdaq
- PRTG Nasdaq
- Market Cap
- WINT 5.3M
- PRTG 4.7M
- IPO Year
- WINT 1995
- PRTG N/A
- Fundamental
- Price
- WINT $0.50
- PRTG $4.69
- Analyst Decision
- WINT Hold
- PRTG Hold
- Analyst Count
- WINT 1
- PRTG 1
- Target Price
- WINT $18.00
- PRTG N/A
- AVG Volume (30 Days)
- WINT 549.5K
- PRTG 42.8K
- Earning Date
- WINT 11-26-2024
- PRTG 12-03-2024
- Dividend Yield
- WINT N/A
- PRTG N/A
- EPS Growth
- WINT N/A
- PRTG N/A
- EPS
- WINT N/A
- PRTG N/A
- Revenue
- WINT N/A
- PRTG N/A
- Revenue This Year
- WINT N/A
- PRTG N/A
- Revenue Next Year
- WINT N/A
- PRTG N/A
- P/E Ratio
- WINT N/A
- PRTG N/A
- Revenue Growth
- WINT N/A
- PRTG N/A
- 52 Week Low
- WINT $0.45
- PRTG $2.10
- 52 Week High
- WINT $22.32
- PRTG $40.80
- Technical
- Relative Strength Index (RSI)
- WINT 27.72
- PRTG 44.83
- Support Level
- WINT $0.45
- PRTG $3.81
- Resistance Level
- WINT $0.64
- PRTG $4.78
- Average True Range (ATR)
- WINT 0.06
- PRTG 0.55
- MACD
- WINT 0.07
- PRTG 0.00
- Stochastic Oscillator
- WINT 19.50
- PRTG 43.16
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.